Voyageur Pharmaceuticals (VYYR.F) Stock Overview
Engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VYYR.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Voyageur Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.097 |
| 52 Week High | CA$0.25 |
| 52 Week Low | CA$0.0033 |
| Beta | 0.36 |
| 1 Month Change | -10.19% |
| 3 Month Change | -25.44% |
| 1 Year Change | n/a |
| 3 Year Change | 90.57% |
| 5 Year Change | -34.33% |
| Change since IPO | 65.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| VYYR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 4.2% |
| 1Y | n/a | 36.0% | 29.0% |
Return vs Industry: Insufficient data to determine how VYYR.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VYYR.F performed against the US Market.
Price Volatility
| VYYR.F volatility | |
|---|---|
| VYYR.F Average Weekly Movement | 19.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: VYYR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VYYR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Brent Willis | voyageurpharmaceuticals.ca |
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products.
Voyageur Pharmaceuticals Ltd. Fundamentals Summary
| VYYR.F fundamental statistics | |
|---|---|
| Market cap | US$14.90m |
| Earnings (TTM) | -US$2.56m |
| Revenue (TTM) | US$8.48k |
Is VYYR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VYYR.F income statement (TTM) | |
|---|---|
| Revenue | CA$11.69k |
| Cost of Revenue | CA$11.69k |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.53m |
| Earnings | -CA$3.53m |
Last Reported Earnings
Nov 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 0% |
| Net Profit Margin | -30,231.56% |
| Debt/Equity Ratio | 3.2% |
How did VYYR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/14 12:33 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/11/30 |
| Annual Earnings | 2025/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Voyageur Pharmaceuticals Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Appiah | Capital Network by Proactive Investors |